[The cyclic administration of nomegestrol acetate does not alter the vasodilating effects of estradiol on the uterine artery]

Contracept Fertil Sex. 1994 Dec;22(12):767-70.
[Article in French]


Uterine artery blood flow was analyzed in 8 menopausal women receiving hormonal replacement therapy consisting of transdermal E2 (0.05 mg/24 h) administered without interruption for 12 weeks in combination with a cyclical supply of Nomegestrol acetate (5 mg/24 h) for the last 13 days of each four week treatment cycle. Uterine artery flow was analyzed using transvaginal pulsed Doppler making semi quantitative measurements of Doppler flow waves by calculation of the pulsatility index (PI). Before treatment (baseline) uterine artery PI was elevated at 3.7 +/- 0.7 (mean +/- SD) and decreased significantly under the influence of E2 to reach 1.9 +/- 0.8 after 2 weeks of treatment. This effect of E2 was not altered by the cyclical addition of Nomegestrol acetate. On the 3rd month of treatment, uterine artery PI values were lower than seen during the first month and no difference was observed between measurements made while receiving E2 (week 10) or E2 and Nomegestrol acetate (week 12). These data indicate that cyclical administration of the progestin Nomegestrol acetate does not interfere with the vascular effects of E2 lowering the uterine artery PI a reflector of the impedance to flow.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Arteries / diagnostic imaging
  • Arteries / drug effects
  • Blood Flow Velocity / drug effects
  • Drug Administration Schedule
  • Estradiol / pharmacology*
  • Estrogen Replacement Therapy / methods*
  • Female
  • Humans
  • Megestrol*
  • Middle Aged
  • Norpregnadienes / pharmacology*
  • Progesterone Congeners / pharmacology*
  • Pulsatile Flow
  • Ultrasonography, Doppler, Pulsed
  • Uterus / blood supply*
  • Vasodilation / drug effects*


  • Norpregnadienes
  • Progesterone Congeners
  • Estradiol
  • nomegestrol acetate
  • Megestrol